Clinical Trial Update: Pulmonary sarcomatoid_MEDI4736+Treme [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of durvalumab and tremelimumab for pulmonary sarcomatoid carcinoma and non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pulmonary Sarcomatoid Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC | Phase 2 | Status: COMPLETED